Replies to post #71 on All Things Energy

[Pro-Life]

These Energy Companies Are Most At Risk From The "Spring Redetermination"
Submitted by Tyler Durden on 03/28/2016 21:48 -0400

http://www.zerohedge.com/news/2016-03-28/these-energy-companies-are-most-risk-spring-borrowing-base-redetermination

Finally, courtesy of Haynes and Boone, here is a less impartial perspective thanks to a poll of banks, PE firms, and oil service companies who were asked to share their thoughts on the upcoming spring redetermination. Among the key findings:

- Overall respondents expect 79% of the borrowers to see a decrease in their borrowing base in spring 2016
- Overall respondents, on average, expect to see borrowing bases to decrease by 38% compared to what they were in fall 2015
- As to the most likely path to be taken by lenders and borrowers who face a borrowing base deficiency this spring: 36% of respondents said the would negotiate an amendment or extension with the lender; 31% said they would sell non-core assets; 15% said they would seek capital from a hedge fund or private equity fund; 4% said sell the company; 13% said restructure or declare bankruptcy

See charts and more including a slide show at the link above...

[BottomBounce]

$AMRS Amyris "Amyris delivers high-performance renewable products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise® in performance or availability.

We developed innovative microbial engineering and screening technologies that modify the way microorganisms process sugars. With our innovative bioscience technology and established fermentation processes, we convert plant-sourced sugars into renewable molecules for multiple applications.

Our story began over a decade ago, when Amyris was founded with a vision of making a positive impact on the world through science. We first used our proprietary process to convert plant-sugars into an alternative, lower cost, stable supply of artemisinin, an effective anti-malarial. Thanks to our breakthrough technology, these life saving drugs are more readily accessible.

Our initial business strategy was focused on the production of Biofene®, Amyris’s brand of renewable farnesene, a long-chain branched hydrocarbon molecule, manufactured using Amyris-engineered microbes in fermentation of plant sugar feedstock.

Building on the expertise from farnesene production, Amyris is developing, and in some cases producing, a range of other molecules. From these renewable molecules, we are developing a wide range of renewable specialty chemicals and fuels products, ranging from cosmetic emollients and fragrances to fuels and lubricants and even biopharmaceuticals, through our µPharm drug discovery platform."

https://amyris.com/our-company/

[BottomBounce]

$AMRS 50DMA Oversold, undervalued $1.50+ coming imo